A Lindqvist

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi request reprint The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation
    L C Laursen
    Department of Lung Medicine, KAS Gentofte, Hellerup, Denmark
    Respir Med 97:S23-33. 2003
  2. pmc Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment
    A R A Sovijarvi
    Department of Clinical Physiology, Helsinki University Central Hospital, Helsinki, Finland
    Thorax 58:500-4. 2003
  3. ncbi request reprint Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma
    P Kuna
    Division of Pneumonology and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland
    Respir Med 100:2151-9. 2006
  4. ncbi request reprint Airway inflammation and basement membrane tenascin in newly diagnosed atopic and nonatopic asthma
    E M Karjalainen
    Clinical Research Unit of Pulmonary Medicine, Department of Medicine, Helsinki University Central Hospital, Finland
    Respir Med 97:1045-51. 2003

Collaborators

Detail Information

Publications4

  1. ncbi request reprint The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation
    L C Laursen
    Department of Lung Medicine, KAS Gentofte, Hellerup, Denmark
    Respir Med 97:S23-33. 2003
    ..These studies, utilizing the novel BCSS, have clearly illustrated that, despite initial symptomatic improvement with sibenadet therapy, this clinical benefit was not sustained over the course of the study...
  2. pmc Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment
    A R A Sovijarvi
    Department of Clinical Physiology, Helsinki University Central Hospital, Helsinki, Finland
    Thorax 58:500-4. 2003
    ..The effect of inhaled fluticasone propionate (FP) on BHR in patients with mild persistent asthma was assessed using time intervals of hours, days and weeks...
  3. ncbi request reprint Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma
    P Kuna
    Division of Pneumonology and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland
    Respir Med 100:2151-9. 2006
    ..Budesonide/formoterol administered once daily in the evening is a convenient treatment regimen that is as effective in improving asthma control as twice-daily dosing in patients with mild to moderate persistent asthma...
  4. ncbi request reprint Airway inflammation and basement membrane tenascin in newly diagnosed atopic and nonatopic asthma
    E M Karjalainen
    Clinical Research Unit of Pulmonary Medicine, Department of Medicine, Helsinki University Central Hospital, Finland
    Respir Med 97:1045-51. 2003
    ..These findings suggest that inflammatory cells may have a regulatory role in tenascin expression in atopic asthma...